Brief: Hillevax And Kangh Announce Exclusive License Agreement For Norovirus Vaccine Candidate Outside Of China

HilleVax

08/01/2024 13:23

Jan 8 (Reuters) - Hillevax Inc  HLVX.O :
    * HILLEVAX AND KANGH ANNOUNCE EXCLUSIVE LICENSE AGREEMENT
FOR
HEXAVALENT VLP NOROVIRUS VACCINE CANDIDATE OUTSIDE OF CHINA
    * HILLEVAX INC - WILL PAY KANGH AN UPFRONT PAYMENT OF $15
MILLION
    * HILLEVAX INC - WILL PAY KANGH UPFRONT PAYMENT WITH
POTENTIAL FOR
EXTRA PAYMENTS OF UP TO $255.5 MILLION UPON ACHIEVING CERTAIN
MILESTONES
    * HILLEVAX INC - KANGH IS ALSO ELIGIBLE TO RECEIVE A
SINGLE-DIGIT
TIERED ROYALTY ON NET SALES OUTSIDE OF GREATER CHINA
    * HILLEVAX - AS PART OF DEAL, KANGH TO SUPPLY HIL-216 FOR
USE IN
CO'S NEAR-TERM CLINICAL TRIALS, INCLUDING PHASE 1 TRIAL CO SEES
TO INITIATE IN 2024

Source text for Eikon:  ID:nGNX1H9mcV 
Further company coverage:  HLVX.O 

 ((Reuters.Briefs@thomsonreuters.com;))